TMCnet News
Research and Markets: OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/bxtbt6/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018" report to their offering. The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL (News - Alert)), currently revolves around multiple rounds of Rituxan-based chemotherapy. Although patients can achieve durable remissions to induction therapy, those patients who relapse after primary treatment have poor progosis and high unmet needs. Several promising pipeline agents are set to have a dramatic impact on treatment of these relapsed/refractory patients over the forecast period: Pharmacyclics'/Janssen's Imbruvica, which was approved for relapsed/refractory MCL patients in November 2013, Gilead's Zydelig, which was approved for relapsed/refractory FL patients in July 2014, and Roche's Gazyva, which will launch in 2015. Key Questions Answered:
Key Topics Covered: 1 List of Tables 2 Introduction 3 Disease Overview 4 Disease Management 5 Epidemiology 6 Current Treatment Options 7 Unmet Needs Assessment and Opportunity Analysis 8 R&D Strategies 9 Pipeline Assessment 10 Pipeline Valuation Analysis 11 Appendix For more information visit http://www.researchandmarkets.com/research/bxtbt6/opportunityanalyze
|